GST to hit GSK Consumer's global growth UK healthcare company GlaxoSmithKline Consumer's growth globally could ease in 2018 due to the impact of India's Goods & Services Tax, the pruning of its product offerings and competitive pressure. "In 2018, we continue to expect low single-digit growth from consumer after factoring in the impact of tail brand divestments, the impact of GST in India, and the TDS generic (competitive pressures in the US), which in aggregate are expected to reduce growth by about 1.5% points on a reported basis," GSK global chief financial officer Simon Dingemans said on an earnings call over the weekend. He added that the company remains confident in the long-term profile of the consumer business. GSK products sold in India include Boost, Horlicks, Crocin and Iodex. India rolled out its biggest tax reform — a unified tax regime under GST — on July 1. Its introduction initially disrupted supplies and companies reported a slowdown i...